Association of glycation markers with the progression of the initial stages of diabetic non-proliferative retinopathy in type 2 diabetes mellitus
DOI:
https://doi.org/10.12775/JEHS.2021.11.03.011Keywords
nonproliferative diabetic retinopathy, type 2 diabetes mellitus, Advanced Glicated End Products, AGE-CML, sRAGEAbstract
Relevance. In the development and progression of non-proliferative diabetic retinopathy (NPDR) in type 2 diabetes mellitus (DM2), an important role belongs to the activity of the protein glycation process and the formation of advanced glycation end products (AGE).Objective: To link glycation markers carboxymethyl lysine (AGE-CML) and circulating AGE receptor (sRAGE) to the progression of early-stage of nonproliferative diabetic retinopathy in patients with type 2 diabetes.Material and methods. 91 patients (182 eyes) with diabetes mellitus aged 42 to 80 years were examined. The control group included 25 people of the appropriate age. At the time of the initial examination and 1 year later, the NPDR stage was established according to the modified ETDRS system of clinical signs Airlie House. The content of glycation markers was determined by enzyme-linked immunosorbent assay in blood plasma. MedStat and MedCalc v.15.1 (MedCalc Software bvba) software packages were used for statistical research.Results. The initial manifestations of diabetic retinal lesions occurred in 27.5% of patients, began after 7.16 ± 1.11 years and were accompanied by higher glycemia. The content of AGE-CML in diabetes mellitus was significantly increased compared to the control, which was more pronounced in the presence of initial retinal changes - was 1.3 times higher than in patients without such changes (p = 0.015). The content of sRAGE decreased several times, which was also associated with the presence of diabetic retinal changes - in their presence it was 2.2 times lower (p <0.001). The content of AGE-CML was significantly higher (1.5 times; p <0.001) in the presence of NPDR progression during 1 year of observation than without it. The content of sRAGE in the presence of progression was 1.6 times (p <0.001) lower. Conclusion. Thus, accumulation of blood AGE-CML and sRAGE reduction is connected with the occurrence and progression of NPDR.Key words: nonproliferative diabetic retinopathy, type 2 diabetes mellitus, Advanced Glicated End Products, AGE-CML, sRAGEReferences
Ulyte A, Bähler C, Schwenkglenks M, von Wyl V, Gruebner O, Wei W, Blozik E, Brüngger B, Dressel H. Measuring diabetes guideline adherence with claims data: systematic construction of indicators and related challenges. BMJ Open. 2019 Apr 24;9(4):e027138. doi: 10.1136/bmjopen-2018-027138
Kowall B, Rathmann W, Stang A, Bongaerts B, Kuss O, Herder C, Roden M, Quante A, Holle R, Huth C, Peters A, Meisinger C. Perceived risk of diabetes seriously underestimates actual diabetes risk: The KORA FF4 study. PLoS One. 2017 Jan 31;12(1):e0171152. doi: 10.1371/journal.pone.0171152.
Heidemann C, Paprott R, Stühmann LM, Baumert J, Mühlenbruch K, Hansen, Schiborn C, Zahn D, Gellert P, Scheidt-Nave Ch. Perceived diabetes risk and related determinants in individuals with high actual diabetes risk: results from a nationwide population-based survey. BMJ. Open Diabetes Res Care. 2019 Jun 21;7(1):e000680. doi: 10.1136/bmjdrc-2019-000680.
Khan RM, Chua ZJ, Tan JC, Yang Y, Liao Z, Zhao Y. From pre-diabetes to diabetes: diagnosis, treatments and translational research. Medicina. Kaunas. 2019 Aug 29;55(9): 546. doi: 10.3390/medicina55090546.
Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: a mini review. Curr Diabetes Rev. 2017;13(1):3-10. doi: 10.2174/1573399812666151016101622.
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-701. doi: 10.2337/dci18-0033.
Tronko MD. [Priority issues of diabetology in Ukraine at the present stage and ways to solve them]. 2020 [Internet]. [cited 20.10.2020]; Available on: http://iem.net.ua/endocrinology_task/ [in Ukrainian]
Nowak MS, Grzybowski A. Rewie of the epidemiology of diabetic retinopathy [Internet]. Modern Retina. Ophtalmology Times. 2018 June 11; Available from: https://www.modernretina.com/diabetic-retinopathy/review-epidemiology-diabetic-retinopathy.
Internetional Diabetes Federation and The Fred Hollows Fundation. Diabetes eye health: A guide for health care professionals. Brussel, Belgium: International Diabetic Federation [Internet]; 2015 [cited 15.07.20]; p. 10. Available from: https://idf.org/our-activities/care-prevention/eye-health/eye-health-guide.html#sub-content-tab-nav.
Kirsch S, Iroku-Malize T. Eye conditions in older adults: diabetic retinopathy. FP Essent. 2016 Jun;445:29-37; quiz 38-9.
Safi H, Safi S, Ali H-M, Hamid A. Early detection of diabetic retinopathy. Survey of Ophthalmology. 2018 Apr; 63 (5): 601-8. doi:10.1016/j.survophthal.2018.04.003.
Voigt M, Schmidt S, Lehmann T, Köhler B, Kloos C, Voigt UA, Meller D, Wolf G, Müller UA, Müller N. Prevalence and Progression Rate of Diabetic Retinopathy in Type 2 Diabetes Patients in Correlation with the Duration of Diabetes. Exp Clin Endocrinol Diabetes. 2018 Sep;126(9):570-6. doi: 10.1055/s-0043-120570.
Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie house classification: ETDRS report № 10. Ophthalmology. 2020 Apr;127(4S): 99-119. doi: 10.1016/j.ophtha.2020.01.030.
Perrone A, Giovino A, Benny J, Martinell F. Advanced glycation end products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects [Internet]. Oxidative Medicine and Cellular Longevity. 2020 Mar 18;2020, doi.org/10.1155/2020/3818196.
Yang P, Feng J, Peng Q, Liu X, Fan Z. Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes [Internet]. Oxidative Medicine and Cellular Longevity. 2019;2019:12. Article ID 9570616. doi.org/10.1155/2019/9570616. Available from: https://www.hindawi.com/journals/omcl/2019/9570616/
Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018 Nov 23;24(1):59. doi: 10.1186/s10020-018-0060-3.
Аltmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018 Jan 1;19(1):110. doi: 10.3390/ijms19010110.
Egaña-Gorroño L, López-Díez1 R, Yepuri G, Ramirez LS, Reverdatto S, Gugger PF, Shekhtman A et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models. [Internet]. Front. Cardiovasc. Med. March 10, 2020. doi.org/10.3389/fcvm.2020.
Kay AM, Simpson CL, Stewart JA. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diab Res. Complic of diab. 2016;2016:6. doi.org/10.1155/2016/6809703.
Scavello F, Zeni F, Tedesco CC, Mensà E, Veglia F, Procopio AD, Bonfigli AR et al. Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging. Aging (Albany NY). 2019 Mar 23;11(6):1648-63. doi: 10.18632/aging.101860.
Zhuoshi W, Xiaxia Y, Ling Xu, Wei He. Relationship of lens advanced glycosylation end products with diabetic retinopathy. [Internet]. Chin J Exp Ophthalmol. 2017;35(1):64-8. Available from: https://cjeo-journal.org/relationship-of-lens-advanced-glycosylation-end-products-with-diabetic-retinopathy/
Ahmad S, Khan H, Siddiqui Z, Khan MY, Rehman S, Shahab U, Godovikova T, Silnikov V, Moinuddin. AGEs, RAGEs and s-RAGE; friend or foe for cancer. Semin Cancer Biol. 2018 Apr;49:44-55. doi: 10.1016/j.semcancer.2017.07.001.
Saleh I, Maritska Z, Parisa N, Hidayat R. Inhibition of Receptor for Advanced Glycation End Products as new promising strategy treatment in Diabetic Retinopathy. Open Access Maced J Med Sci. 2019 Oct 14;7(23):3921-4. doi: 10.3889/oamjms.2019.759.
Khan R, Ooi XY, Parvus M, Valdez L, Tsin A. Advanced glycation end products: formation, role in diabetic complications, and potential in clinical applications [Internet]. IntechOpen. 2019 Oct 3rd; doi: 10.5772/intechopen.89408. Available from: https://www.intechopen.com/online-first/advanced-glycation-end-products-formation-role-in-diabetic-complications-and-potential-in-clinical-a.
Iqbal Z, Morahan G, Arooj M, Sobolev AN, Hameed S. Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress. Eur J Med Chem. 2019 Apr 15;168:154-75. doi: 10.1016/j.ejmech.2019.02.036.
Liu C, Ge H-M, Liu B-H, Dong R, Shan K, Chen Xue, Yao M-D, Li X-M, Yao J, Zhou R-M, Zhang S-J, Jiang Q, Zhao C, Yan B. Targeting pericyte-endothelial cell crosstalk by circular RNA-cPWWP2A inhibition aggravates diabetes-induced microvascular dysfunction. Proc Natl Acad Sci USA. 2019 Apr 9;116(15):7455-64. doi: 10.1073/pnas.1814874116.
Moemen LA, Abdel-Hamid MA, Wahab SA, Kenawy M, Abuelela MH, Hassanin OA, Fouly MA, Abdelazeem AA et al. Role of advanced glycation end products and sorbitol dehydrogenase in the pathogenesis of diabetic retinopathy. Bull Natl Res Cent 44. 2020 Apr 19;58. doi: 10.1186/s42269-020-00304-0.
Mogilevskyy SIu, Bushuieva OV, Ziablitsev S V, Natrus LV. Relationship of the AKR1B1 rs759853 and rs9640883 with the development of diabetic retinopathy. J.ophthalmol.(Ukraine). 2017;2:3-7. doi: 10.31288/oftalmolzh2017237.
Chuang PY, Dai Y, Liu R, He H, Kretzler M, Jim B, Cohen CD, He JC. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One. 2011;6(8):e23566. doi: 10.1371/journal.pone.0023566.
Xu J, Chen LJ, Yu J, Wang HJ, Zhang F, Liu Q, Wu J. Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy. Cell Physiol Biochem. 2018;48(2):705-717. doi: 10.1159/000491897.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 557
Number of citations: 0
